The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Subscribe To Our Newsletter & Stay Updated
